Foreign media: AbbVie is in talks to acquire Revolution Medicines, with a valuation potentially exceeding $20 billion
On January 7, Eastern Time, The Wall Street Journal reported that AbbVie is in advanced talks to acquire Revolution Medicines, a biotechnology company specializing in cancer drugs, with a valuation potentially reaching $20 billion or more. The report stated that a deal could be reached soon, barring any last-minute obstacles.
Source:富途快讯 · Source Link
Disclaimer: This content reflects only the author’s personal views and does not constitute any investment or financial advice. If you discover any content that violates regulations,Click to Report
24H Trending
-
1
What Is LBY? An Analysis of the Libonomy and Lobby Projects and Their Prospects
-
2
A Guide to the Legality of Cryptocurrency Trading Apps and How to Identify Legitimate Platforms
-
3
OXBULL (OXB) Token Analysis: Project Positioning, Current Status, and Future Prospects
-
4
Analysis of BBT Token Value: Current Status of the BitBook Project and Investment Risk Assessment
-
5
What Is LITH? An Analysis of the Lithium Finance Token’s Features and Trading Platforms
-
6
Exchanging USDC for Chinese Yuan: How-To Guide and Important Notes
-
7
What Is WNRG? An Analysis of the Wrapped Energi Token and Where to Trade It
-
8
What Is RBG? An Analysis of the Cryptocurrency of the Same Name and the Bitcoin Smart Contract Protocol
-
9
Guide to Joining the Official Crypto.com Coin (CRO) Community Group and Security Tips
-
10
PSG Token Trading Guide: An Overview of Listed Exchanges and How to Buy
Markets Today
Recommended Reading












